Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1973 1
1974 1
1979 1
1981 1
1984 1
1991 1
1994 2
1996 1
1999 1
2000 2
2003 1
2006 1
2008 1
2009 1
2010 1
2013 1
2020 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

20 results
Results by year
Filters applied: . Clear all
Page 1
Nucleotide P2Y1 receptor agonists are in vitro and in vivo prodrugs of A1/A3 adenosine receptor agonists: implications for roles of P2Y1 and A1/A3 receptors in physiology and pathology.
Liston TE, Hinz S, Müller CE, Holstein DM, Wendling J, Melton RJ, Campbell M, Korinek WS, Suresh RR, Sethre-Hofstad DA, Gao ZG, Tosh DK, Jacobson KA, Lechleiter JD. Liston TE, et al. Among authors: melton rj. Purinergic Signal. 2020 Dec;16(4):543-559. doi: 10.1007/s11302-020-09732-z. Epub 2020 Oct 31. Purinergic Signal. 2020. PMID: 33129204 Free PMC article.
First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies.
Weiss GJ, Chao J, Neidhart JD, Ramanathan RK, Bassett D, Neidhart JA, Choi CHJ, Chow W, Chung V, Forman SJ, Garmey E, Hwang J, Kalinoski DL, Koczywas M, Longmate J, Melton RJ, Morgan R, Oliver J, Peterkin JJ, Ryan JL, Schluep T, Synold TW, Twardowski P, Davis ME, Yen Y. Weiss GJ, et al. Among authors: melton rj. Invest New Drugs. 2013 Aug;31(4):986-1000. doi: 10.1007/s10637-012-9921-8. Epub 2013 Feb 9. Invest New Drugs. 2013. PMID: 23397498 Free PMC article. Clinical Trial.
20 results